^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Koselugo (selumetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

    Excerpt:
    ...Patients must have biopsy proven K-RAS mutant, metastatic colorectal cancer that has progressed on at least 2 prior standard therapies....
    Trial ID:
    NCT01287130
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

    Excerpt:
    ...Patients must have biopsy proven K-RAS mutant, metastatic colorectal cancer that has progressed on at least 2 prior standard therapies; K-RAS mutation status must be verified by a CLIA-certified laboratory (...
    Trial ID:
    NCT01217450
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Invest New Drugs
    Title:

    A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

    Excerpt:
    The combination of selumetinib and cetuximab is safe and well tolerated. Minimal anti-tumor activity was observed in KRAS-mutant refractory metastatic CRC.
    DOI:
    10.1007/s10637-015-0314-7
    Trial ID:
    NCT01287130